Dimethyl fumarate: A possible exit strategy from natalizumab treatment in patients with multiple sclerosis at risk for severe adverse events
Journal of Neurology, Neurosurgery & Psychiatry | Sep 07, 2017
Journal of Neurology, Neurosurgery & Psychiatry | Sep 07, 2017